Sickle-cell anemia is a very frequent genetic disease of the blood which is common in populations with origins in Central and West Africa. It is characterized by vaso-occlusive ischemic accidents which can lead to ulcerations of the skin.
Pre-clinical cell therapy study
- Reference laboratory: I-Stem
Reconstitution of the epidermis using embryonic stem cells constitutes a therapeutic alternative in the treatment of genodermatoses and other cutaneous diseases such as ulcerations and burns. A first cell therapy trial is in preparation for ulcers due to sickle-cell anemia. The clinical trial, which is planned for 2013, aims to validate the treatment of these ulcerations by a biological bandage. Its principle is that of grafts used for severe burns, but in this case with epidermic substitutes obtained from hES cells, standardized and controlled in the laboratory under GMP conditions.